Pharming Group N.V. — Form 6-K Summary
Business context and reporting period
Pharming Group N.V., a Netherlands-based global biopharmaceutical company, filed a Form 6-K for April 2022 dated April 22, 2022. The filing reports a change in Pharming’s minority investment in BioConnection B.V., a contract development and manufacturing organization and long-time fill-and-finish partner for RUCONEST.
Key financial and operating metrics
- Pharming’s ownership interest in BioConnection will decrease from 43.85% to 22.98%.
- Pharming expects to receive one-time net cash proceeds of US$7.5 million, or €6.9 million, in the second quarter of 2022.
- Pharming originally invested €4.1 million in BioConnection in April 2019 through its wholly owned subsidiary, Pharming Technologies B.V.
- The filing does not provide revenue, profit, operating cash flow, margin, debt, liquidity, or other period-specific financial results.
Material changes versus the prior comparable period
The material change is the restructuring of Pharming’s BioConnection investment following an offer by European investment company Gimv. Existing shareholders agreed to sell all issued and outstanding BioConnection shares to a new Gimv-incorporated holding company, followed by partial reinvestment by existing shareholders. Pharming will retain a reduced minority stake and receive cash proceeds.
Outlook, commentary, risks, and unusual items
Pharming stated that it will continue supporting BioConnection alongside Gimv and other shareholders. The stated objective is to support BioConnection’s growth, including investment in its organization, infrastructure, and production capacity.
The one-time €6.9 million net cash receipt is an unusual transaction-related item. The filing does not provide guidance for Pharming’s revenue, earnings, or cash flow.
Forward-looking statements remain subject to risks and uncertainties involving clinical trials, development costs, clinical, scientific, regulatory and technical developments, COVID-19-related business effects, working-capital requirements, and cash resources. Pharming refers investors to its 2021 Annual Report and 2021 Form 20-F for additional risks.
Important facts for investors to verify
- Completion and timing of the BioConnection transaction and receipt of the stated Q2 2022 cash proceeds.
- Accounting treatment and any gain, loss, or other impact from reducing Pharming’s ownership interest.
- Pharming’s continuing rights, obligations, and influence associated with its 22.98% BioConnection stake.
- BioConnection’s capacity-expansion plans and implications for RUCONEST supply.
- Any subsequent updates to Pharming’s liquidity, working-capital outlook, and broader financial guidance.